Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)

K. Newbold, P. Schoeffski, B. Hasan, L. D. Locati, Y. Godbert, C. de la Fouchardiere, L. Bastholt, M. Fassnacht, N. Reed, Y. Lalami, C. Chougnet, C. Schvartz, E. Kapiteijn, M. J. Schlumberger, W. Sents, N. Sauve, S. Leboulleux

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article number1919P
JournalAnnals of Oncology
Volume31
Issue numberSuppl. 4
Pages (from-to)S1087-S1088
ISSN0923-7534
DOIs
Publication statusPublished - 1. Sept 2020
EventESMO Virtual Congress -
Duration: 19. Sept 202018. Oct 2020

Conference

ConferenceESMO Virtual Congress
Period19/09/202018/10/2020

Cite this